News Archives

A Message of Thanks to All Our Backers

You have donated a grand total of $7,035, 156% of our funding goal. Your generous support has enabled the studies to begin in two weeks when we start the process of testing our hypothesis: Can Effective Targeted Delivery of Curcumin

Posted in News

Science Crowdfunding Campaign Exceeds Funding Goal

We are very pleased to report success in pledges of $6448 from the public at a Science Crowdfunding Platform. This is 143% of our original funding goal of $4500, permitting us to begin a preclinical Proof of Concept study in

Posted in News

Augustus BioTarget starting a targeted cancer treatment study this fall

Augustus BioTarget is starting a targeted cancer treatment study with curcumin encapsulated in the Rodos CLR/ TargoSphere this October in a colon cancer mouse model.

Posted in News

Drug Development in Alzheimer’s Disease: the Path to 2025

Jeffrey Cummings, Paul S. Aisen, Bruno DuBois, Lutz Frölich, Clifford R. JackJr, Roy W. Jones, John C. Morris, Joel Raskin, Sherie A. Dowsett and Philip Scheltens From: Alzheimer’s Research & Therapy Sept. 2016; 20168:39 The global impact of Alzheimer’s disease

Posted in News

Rodos Biotarget will host ‘Future Medicine Symposium’

Augustus BioTarget is using a specialized Rodos nanocarrier to target the immune system in the development of a new treatment for Alzheimer’s disease. Hannover, Germany, 28 October 2016. A biopharmaceutical company, Rodos Biotarget joins the ranks of industry leadership in

Posted in News

We are developing an Immunotherapeutic Approach to the Treatment of Early and Mid-Stage Alzheimer Dementias

Invest in EquityNet Crowdfunding to Help Develop Our New Alzheimer Treatment: www.equitynet.com/c/augustus-biotarget-inc For more information visit the Alzheimer’s Disease Project page.

Posted in News